Recent policy developments in the European Union and elsewhere aim to tackle some of the key issues responsible for the limited adoption of personalized medicine approaches so far.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Blood glutamine synthetase signaling in alcohol use disorder and racial disparity
Translational Psychiatry Open Access 22 February 2022
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Acknowledgements
M.P. and C.N. are supported by the County of Salzburg and FP7-PIRSES- GA-2008-230661 or PMU-FFF-E-12/15/075.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary information S1 (box)
Further regulatory documents related to personalized medicine (PDF 61 kb)
Rights and permissions
About this article
Cite this article
Nofziger, C., Papaluca, M., Terzic, A. et al. Policies to aid the adoption of personalized medicine. Nat Rev Drug Discov 13, 159–160 (2014). https://doi.org/10.1038/nrd4257
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd4257
This article is cited by
-
Blood glutamine synthetase signaling in alcohol use disorder and racial disparity
Translational Psychiatry (2022)
-
Pharmacogenomic information in drug labels: European Medicines Agency perspective
The Pharmacogenomics Journal (2015)